Sam Shrivastava

Sam Shrivastava

Company: Venn Therapeutics

Job title: Chairman & CEO


Integrin αvβ8-Expressing Tumor Cells Serve as a Platform for TGF-ß Activation 1:00 pm

This discovery offers a promising novel target to safely and effectively overcome TGF-β-driven immuno-suppression in a variety of tumor types. • Venn Therapeutics is driven by a paradigm-shifting discovery by Dr. Stephen Nishimura on how transforming growth factor-beta (TGF-β) is activated by integrin αvβ8, published in Cell in January 2020. Dr. Nishimura’s paper showed that…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.